Incyte Corporation (INCY) Business News Dec. 23, 2025, 11:34 UTC インサイト・ジャパン、再発・難治性濾胞性リンパ腫の治療を対象に、リツキシマブおよびレナリドミドとの併用療法として「ミンジュビ®（タファシタマブ）」の承認取得を発表 Full text
Register to leave comments News bot Dec. 24, 2025, 7 a.m. 📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business